Trial Profile
A Dose Escalation Study to Assess the Efficacy and Tolerance of AF-219 in Subjects With Refractory Chronic Cough
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 14 Dec 2023
Price :
$35
*
At a glance
- Drugs Gefapixant (Primary)
- Indications Cough
- Focus Therapeutic Use
- Sponsors Afferent Pharmaceuticals
- 29 Sep 2020 Number of treatment arms has been increased from 2 to 4, dividing the enrolled patients into 2 cohorts-- cohort 1 and 2 and further dividing both these cohorts into 2 groups namely- Gefapixant greater than Placebo and Placebo greater than Gefapixant- comprising different doses of the primary drug. The total number of primary end-points has been increased to 6.
- 16 Mar 2020 Results evaluating comorbid conditions and secondary diagnoses associated with cough using two phase II trials (NCT02349425 and NCT02612610) presented at the 2020 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 16 Jan 2020 Results evaluating the dose response of gefapixant in reducing awake objective cough frequency and identifying tolerable doses through the evaluation of low and high-dose cohorts using 2 randomised , double blind, placebo contolled trials published in the European Respiratory Journal